S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:HRTX

Heron Therapeutics News Headlines

$8.38
-0.15 (-1.76%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.27
$8.83
50-Day Range
$8.14
$11.24
52-Week Range
$8.05
$20.45
Volume
2.27 million shs
Average Volume
1.80 million shs
Market Capitalization
$854.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.34
Get Heron Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Heron Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

HRTX
News Sentiment

0.32

0.41

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

HRTX Articles
This Week

1

1

HRTX Articles
Average Week



Heron Therapeutics (NASDAQ:HRTX) News Headlines Today

SourceHeadline
MarketBeat logoHeron Therapeutics (NASDAQ:HRTX) Shares Gap Up to $8.53
americanbankingnews.com - January 21 at 11:50 AM
MarketBeat logoHeron Therapeutics (NASDAQ:HRTX) Sets New 52-Week Low at $8.22
americanbankingnews.com - January 14 at 1:54 PM
MarketBeat logoHeron Therapeutics (NASDAQ:HRTX) Shares Gap Up to $8.50
americanbankingnews.com - January 13 at 10:46 AM
finance.yahoo.com logoWhy Heron Therapeutics Shares Rose Nearly 15% This Week
finance.yahoo.com - December 9 at 5:58 PM
nasdaq.com logoHeron Therapeutics: FDA Approves Expanded Indication For ZYNRELEF
nasdaq.com - December 9 at 12:58 PM
markets.businessinsider.com logoFDA Approves Indication Expansion For Heron Therapeutics' Post-Op Pain Med
markets.businessinsider.com - December 9 at 12:58 PM
finance.yahoo.com logoHeron Therapeutics Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF®
finance.yahoo.com - December 9 at 12:58 PM
finance.yahoo.com logo2 Short-Squeeze Candidates That Could Go Parabolic Soon
finance.yahoo.com - December 9 at 12:58 PM
finance.yahoo.com logoHeron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA
finance.yahoo.com - November 18 at 8:11 AM
finance.yahoo.com logoHeron Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - November 11 at 6:14 PM
finance.yahoo.com logoHeron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Recent Corporate Updates
finance.yahoo.com - November 3 at 6:52 PM
finance.yahoo.com logoHeron Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 3, 2021
finance.yahoo.com - October 28 at 9:44 AM
seekingalpha.com logoHRTX
seekingalpha.com - October 28 at 12:33 AM
finance.yahoo.com logoSHAREHOLDER ALERT: HRTX EQT FRED: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
finance.yahoo.com - October 26 at 1:58 AM
finance.yahoo.com logoBluebird Bio or Heron Therapeutics: Which Stock Is the Better Comeback Play?
finance.yahoo.com - October 11 at 1:44 PM
nasdaq.com logoHeron Therapeutics Inc Shares Near 52-Week Low - Market Mover
nasdaq.com - October 9 at 7:28 PM
finance.yahoo.com logoHeron Therapeutics Announces Filing of a Supplemental New Drug Application for Significant Expansion of ZYNRELEF® Indication Statement Based on Successful Outcome of FDA Type C Meeting
finance.yahoo.com - October 4 at 1:12 PM
finance.yahoo.com logoHRTX Oct 2021 13.000 put
finance.yahoo.com - September 29 at 4:30 PM
benzinga.com logoHeron Therapeutics's Return On Capital Employed Overview
benzinga.com - September 21 at 2:33 PM
finance.yahoo.com logo2 “Strong Buy” Stocks With Heavy Short Interest
finance.yahoo.com - September 13 at 10:20 PM
nasdaq.com logoSome Heron Therapeutics, Inc. (NASDAQ:HRTX) Analysts Just Made A Major Cut To Next Year's Estimates
nasdaq.com - August 15 at 4:50 PM
finance.yahoo.com logoThese Analysts Just Made A Significant Downgrade To Their Heron Therapeutics, Inc. (NASDAQ:HRTX) EPS Forecasts
finance.yahoo.com - August 15 at 4:50 PM
finance.yahoo.com logoHeron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 9 at 1:26 PM
finance.yahoo.com logoHeron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Recent Corporate Updates
finance.yahoo.com - August 9 at 8:26 AM
finance.yahoo.com logoHeron Therapeutics (NASDAQ:HRTX) Share Prices Have Dropped 66% In The Last Three Years
finance.yahoo.com - July 31 at 2:13 PM
finance.yahoo.com logoWill Heron Therapeutics (HRTX) Report Negative Q2 Earnings? What You Should Know
finance.yahoo.com - July 28 at 7:19 PM
finance.yahoo.com logoHeron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNRELEF™ Minimizes the Need for Opioids in a Real-World Setting, With 95% of Patients Experiencing an Opioid-free Recovery
finance.yahoo.com - July 28 at 7:19 PM
markets.businessinsider.com logoHeron Therapeutics' Zynrelef Shows Reduction In Post-Op Pain, Opioid Use Compared To Bupivacaine In Old-Aged Patients
markets.businessinsider.com - July 22 at 8:14 AM
finance.yahoo.com logoHeron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™
finance.yahoo.com - July 21 at 5:51 PM
uk.finance.yahoo.com logoHRTX Jul 2021 20.000 call
uk.finance.yahoo.com - July 17 at 9:41 PM
nasdaq.com logoHeron Therapeutics, Inc. Common Stock (HRTX)
nasdaq.com - July 16 at 10:47 PM
markets.businessinsider.com logoHeron Therapeutics Executes Contract With Apexus For Non-opioid Option ZYNRELEF
markets.businessinsider.com - July 6 at 10:06 AM
finance.yahoo.com logoHeron Therapeutics Announces 340B Prime Vendor Contract with Apexus for ZYNRELEF™
finance.yahoo.com - July 6 at 10:06 AM
uk.finance.yahoo.com logoHRTX Jul 2021 17.000 call
uk.finance.yahoo.com - July 3 at 8:31 AM
benzinga.com logoHeron Therapeutics Announces U.S. Commercial Launch, Availability Of ZYNRELEF For Management Of Postoperative Pain For Up To 72 Hours
benzinga.com - July 1 at 1:18 PM
finance.yahoo.com logoHeron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF™ for the Management of Postoperative Pain for up to 72 Hours
finance.yahoo.com - July 1 at 1:18 PM
nasdaq.com logoHere's Why Shareholders May Want To Be Cautious With Increasing Heron Therapeutics, Inc.'s (NASDAQ:HRTX) CEO Pay Packet
nasdaq.com - June 11 at 5:33 PM
finance.yahoo.com logoHeron Therapeutics to Present at the 2021 Jefferies Virtual Investor Conference
finance.yahoo.com - May 25 at 6:07 PM
finance.yahoo.com logoHeron Therapeutics Announces $150 Million Convertible Debt Financing
finance.yahoo.com - May 25 at 1:06 PM
finance.yahoo.com logoHeron's stock rises after FDA approval of surgical medicine
finance.yahoo.com - May 13 at 2:25 PM
marketwatch.com logoHeron Therapeutics Gets FDA OK of Zynrelef for Postoperative Pain >HRTX
marketwatch.com - May 13 at 9:25 AM
nasdaq.com logoHeron Therapeutics' Zynrelef Gets FDA Approval For Managing Post-Operative Pain For 72 Hours
nasdaq.com - May 13 at 9:25 AM
finance.yahoo.com logoHeron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours
finance.yahoo.com - May 13 at 9:25 AM
benzinga.com logoHeron Stock Trading Higher After Q1 Earnings, Ahead Of HTX-011 Decision Scheduled This Week
benzinga.com - May 10 at 4:15 PM
finance.yahoo.com logoHeron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Recent Corporate Updates
finance.yahoo.com - May 10 at 4:15 PM
finance.yahoo.com logoHeron Therapeutics (HRTX) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 10 at 4:15 PM
finance.yahoo.com logoWhy Heron Therapeutics Stock Jumped Today
finance.yahoo.com - May 10 at 4:15 PM
nasdaq.com logoHRTX Makes Notable Cross Below Critical Moving Average
nasdaq.com - May 4 at 1:32 PM
finance.yahoo.com logoWill Heron Therapeutics (HRTX) Report Negative Q1 Earnings? What You Should Know
finance.yahoo.com - April 28 at 1:40 PM
nasdaq.com logoHeron Therapeutics'(NASDAQ:HRTX) Share Price Is Down 43% Over The Past Three Years.
nasdaq.com - April 28 at 8:39 AM
Get Heron Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.